New York, October 13, 2016 -- Moody's Investors Service ("Moody's") affirmed Horizon Pharma, Inc.'s , B2 Corporate Family Rating, B2-PD Probability of Default Rating, Ba2 senior secured rating and SGL-2 Speculative Grade Liquidity Rating. At the same time, Moody's lowered the senior unsecured rating to B3 from B2. Moody's also assigned ratings to the new debt instruments including a Ba2 senior secured rating and B3 senior unsecured rating. The rating outlook is stable.
Vollständigen Artikel bei Moodys lesen